论文部分内容阅读
目的:探讨以国产地西他滨为主的方案治疗中高危组骨髓增生异常综合征(MDS)的临床疗效及不良反应。方法:回顾性分析接受国产地西他滨联合半量CAG方案治疗的34例中高危组MDS的临床资料,评价其疗效和不良反应。结果:34例MDS患者中,完全缓解6例,部分缓解11例,血液学改善9例,疾病进展6例,死亡2例,完全缓解率17.6%,有效率50.0%。血液学不良反应发生率100%,感染发生率94.1%,死亡率5.9%。结论:以国产地西他滨为主的化疗方案可有效治疗MDS,虽然血液学不良反应较重,感染的发生率较高,但患者基本上可耐受,给予相应抗炎及支持治疗可得到有效控制,与同类进口药物比较,具有明显的价格优势和相近的疗效。
Objective: To investigate the clinical efficacy and side effects of domestic solution of decitabine in the treatment of middle-high risk group myelodysplastic syndrome (MDS). Methods: The clinical data of 34 MDS patients receiving middle-dose and high-risk decitabine plus decitabine plus half-dose CAG regimen were retrospectively analyzed to evaluate their efficacy and adverse reactions. Results: Of the 34 patients with MDS, complete remission was achieved in 6, partial remission in 11, hematologic improvement in 9, disease progression in 6, and death in 2. The complete remission rate was 17.6% and the effective rate was 50.0%. The incidence of adverse reactions to hematology was 100%, the incidence of infection was 94.1% and the mortality rate was 5.9%. CONCLUSIONS: The decitabine-based chemotherapy regimen is effective in treating MDS. Although hematologic adverse reactions are severe and the incidence of infection is high, patients are basically tolerated. Corresponding anti-inflammatory and supportive care are available Effective control, compared with similar imported drugs, has obvious price advantage and similar curative effect.